Reference priceJPY ¥770.00Original source price: INR 440.00. Converted estimates are available by currency selection.
| Brand | Zyclara |
|---|---|
| Manufacturer | MYLAN PHARMACEUTICALS, S.L. |
| Prescription required | Yes |
Zyclara 3.75% Creme 28envases x 0.25mg(Imiquimod)
imiquimod
Description
Zyclara 3.75% Creme 28envases x 0.25mg(Imiquimod) is a medicine catalog record in the MediPriceHub database. Active ingredient: imiquimod. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: MYLAN PHARMACEUTICALS, S.L.. Therapeutic category: Medicine Library > Dermatology Medicines > Solar keratosis drugs. Pack information: 28 250. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
• ZYCLARA 2.5% and 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. • ZYCLARA, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older.How to Use
Use imiquimod under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: imiquimod. Pack size: 28 250. Pack unit: box. Manufacturer: MYLAN PHARMACEUTICALS, S.L.. Origin country: Spain. Source category: Medicine Library > Dermatology Medicines > Solar keratosis drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Possible adverse effects vary by active ingredient, dose, route, treatment duration, and patient condition. Common issues may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, allergic reactions, or abnormal laboratory tests. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。